Table 4.

Effects of ancillary therapies used in combination with an antimicrobial on clinical severity scores, rectal temperatures, and mortalities and removals

Variable	Experimental ancillary treatment1				Pooled SEM	Overall P-value2
	NOAC	NSAID	VACC	VITC
Severity score3
First treatment	1.14a,x	1.13a,x	1.04b,y	1.18a	0.06	0.06
Second treatment	2.37a	2.83c	2.53ab	2.69b,c	0.27	<0.01
Third treatment	2.50a	2.84b	2.98b	3.11b	0.23	<0.01
Fourth treatment	2.84	3.05	2.99	2.83	0.30	0.72
Rectal temperature,4 °C
First treatment	40.7	40.7	40.8	40.8	0.08	0.27
Second treatment	40.3	40.3	40.5	40.3	0.19	0.87
Third treatment	39.6	39.4	39.4	39.4	0.33	0.86
Fourth treatment	39.5	39.4	39.0	39.1	0.31	0.55
Off trial, %
Mortality	17.5	22.5	20.0	23.8	8.97	0.74
Removals5	6.17a	0.00b	3.65a,b	1.16b	1.92	0.08
Combined off trial6	23.8	22.5	23.8	25.0	9.85	0.98

^a–cWithin a row means with different superscripts differ (P ≤ 0.05).

^x,yWithin a row means with different superscripts tend to differ (P ≤ 0.10).

¹Experimental ancillary therapy treatments administered at each antimicrobial treatment for bovine respiratory disease: NOAC = antimicrobial only, no ancillary therapy; NSAID = intravenous flunixin meglumine injection; VACC = revaccination with an intranasal viral vaccine; VITC = intramuscular vitamin C injection.

² P-values are included for the overall F test.

³Subjective clinical severity score (1 = mild clinical signs, 2 = moderate clinical signs, 3 = severe clinical signs, and 4 = extreme clinical signs or a moribund animal) assigned by trained personnel. For a calf to be assigned a clinical severity score of 4, the calf had to be unable to rise or had to have extreme difficulty standing, walking, or breathing.

⁴Rectal temperature at the time of bovine respiratory disease (BRD) treatment.

⁵Percentage of calves removed from the experiment because of lameness or the inability to compete in the home pen (includes surviving chronic BRD cases).

⁶Combined percentage of mortalities and removals for the experiment.